Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 275Lung Neoplasms 106Adenocarcinoma of Lung 27Mesothelioma, Malignant 22Neoplasms 19Neoplasm Metastasis 18Breast Neoplasms 13Brain Neoplasms 13Mesothelioma 10Head and Neck Neoplasms 10Ovarian Neoplasms 8Colorectal Neoplasms 8Recurrence 7Adenocarcinoma, Bronchiolo-Alveolar 7Small Cell Lung Carcinoma 6NSCLC 6Adenocarcinoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Meningeal Carcinomatosis 5Carcinoma 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Solitary Fibrous Tumor, Pleural 4Sarcoma 4Pancreatic Neoplasms 4Non-small Cell Lung Cancer Metastatic 4Laryngeal Diseases 4Carcinoma, Transitional Cell 4Uterine Neoplasms 3Uterine Cervical Neoplasms 3

Interventions

Paclitaxel 2Cisplatin 2Carboplatin 2osimertinib 1cemiplimab 1Surgical Procedures, Operative 1Pemetrexed 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Resectable Non-small Cell Lung Cancer × Pemetrexed × Clear all
NCT06161441 2026-01-12

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡